Global Antibody Drug Conjugate research
Global Antibody Drug Conjugate research

Antibody Drug Conjugate Comprehensive Study by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor), Payloads (Auristatin Derivatives, Maytansinoids, Calicheamicin, Others), Conjugates (Small Molecules, Protein Toxin, Cytolytic Immunomodulatory Protein, Biologically Active Peptide, Enzymes, Radionuclides), Linker (Cleavable Linker, Non-Cleavable Linker), Indications (Breast Cancer, Lymphoma (Hl, Nhl, Alcl), Leukemia (Aml, All), Urothelial Cancer, Lung Cancer (Nsclc, SCLC),, Others), Route Of Administration (Enteral Route, Parenteral Route) Players and Region - Global Market Outlook to 2025

Antibody Drug Conjugate Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 237 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Antibody Drug Conjugate Market?

Over the years, a number of companies(small or well-funded start-ups), offering novel conjugation technologies, more potent warheads, and advanced linker technologies, have been established. Moreover, the multiple collaborations licensing agreements, have been inked in the past few years between technology providers and drug developers to advance the development of pipeline Antibody Drug Conjugate candidates. Antibody-Drug Conjugates is a matter made up of a monoclonal antibody chemically linked to a drug. The monoclonal antibody binds to specific proteins on certain types of cells, such as cancer cells. These drug enters these cells and kills them without harming other cells. Some antibody-drug conjugates are used to treat cancer. Also called ADC. According to the research done by the World Health Organization, in 2018 some 18 million people around the world were diagnosed with cancer and some 9.6 million died of the disease. Cancers of the digestive organs, lungs are more common, affecting both men and women, while breast and cervical cancer are naturally prevalent among women. The growing popularity and therapeutic possiblity of Antibody Drug Conjugate can also be correlated with an exponential rise in the number of patents that have been granted

The market study is being classified, by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer and Brain Tumor) and major geographies with country level break-up.

Pfizer (United States), Progenics Pharmaceuticals(United States), Novartis (Switzerland), Eli Lilly(United States), Genentech(United States), Genmab (Denmark), Amgen (United States), Bayer HealthCare (Germany), Celldex Therapeutics(United States) and Concortis Biotherapeutics(United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Mersana Therapeutics(United States), Millennium Pharmaceuticals(United States), AbbVie (United States) and Agensys(United States).

The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Antibody Drug Conjugate market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Antibody Drug Conjugate market by Type, Application and Region.

On the basis of geography, the market of Antibody Drug Conjugate has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • The Growing Geriatric Population Is Expected To Drive Growth Of The Market Over The Forecast Period.
  • Increasing Incidence Of Cancer Coupled With Growing Geriatric Population

Market Trend
  • Emergence Of Cancer Treatment Options

Restraints
  • The adverse effect of the treatment

Opportunities
  • Innovative Drug Development Opening A New Horizon In Cancer Therapy

Challenges
  • High cost of the treatment


Market Leaders and some development strategies
In September 2020 Gileadís the United States Based Phamacitiucals Company Has USD 21 Billion Purchase Of Immunomedics Boosts ADC Field.



Key Target Audience
Antibody-Drug Conjugate Providers, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumor
By Payloads
  • Auristatin Derivatives
  • Maytansinoids
  • Calicheamicin
  • Others

By Conjugates
  • Small Molecules
  • Protein Toxin
  • Cytolytic Immunomodulatory Protein
  • Biologically Active Peptide
  • Enzymes
  • Radionuclides

By Linker
  • Cleavable Linker
  • Non-Cleavable Linker

By Indications
  • Breast Cancer
  • Lymphoma (Hl, Nhl, Alcl)
  • Leukemia (Aml, All)
  • Urothelial Cancer
  • Lung Cancer (Nsclc, SCLC),
  • Others

By Route Of Administration
  • Enteral Route
  • Parenteral Route

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Growing Geriatric Population Is Expected To Drive Growth Of The Market Over The Forecast Period.
      • 3.2.2. Increasing Incidence Of Cancer Coupled With Growing Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. High cost of the treatment
    • 3.4. Market Trends
      • 3.4.1. Emergence Of Cancer Treatment Options
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antibody Drug Conjugate, by Application, Payloads , Conjugates, Linker, Indications, Route Of Administration and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Antibody Drug Conjugate (Value)
      • 5.2.1. Global Antibody Drug Conjugate by: Application (Value)
        • 5.2.1.1. Blood Cancer
        • 5.2.1.2. Breast Cancer
        • 5.2.1.3. Ovarian Cancer
        • 5.2.1.4. Lung Cancer
        • 5.2.1.5. Brain Tumor
      • 5.2.2. Global Antibody Drug Conjugate by: Conjugates (Value)
        • 5.2.2.1. Small Molecules
        • 5.2.2.2. Protein Toxin
        • 5.2.2.3. Cytolytic Immunomodulatory Protein
        • 5.2.2.4. Biologically Active Peptide
        • 5.2.2.5. Enzymes
        • 5.2.2.6. Radionuclides
      • 5.2.3. Global Antibody Drug Conjugate by: Indications (Value)
        • 5.2.3.1. Breast Cancer
        • 5.2.3.2. Lymphoma (Hl, Nhl, Alcl)
        • 5.2.3.3. Leukemia (Aml, All)
        • 5.2.3.4. Urothelial Cancer
        • 5.2.3.5. Lung Cancer (Nsclc, SCLC),
        • 5.2.3.6. Others
      • 5.2.4. Global Antibody Drug Conjugate by: Route Of Administration (Value)
        • 5.2.4.1. Enteral Route
        • 5.2.4.2. Parenteral Route
      • 5.2.5. Global Antibody Drug Conjugate Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Antibody Drug Conjugate (Volume)
      • 5.3.1. Global Antibody Drug Conjugate by: Application (Volume)
        • 5.3.1.1. Blood Cancer
        • 5.3.1.2. Breast Cancer
        • 5.3.1.3. Ovarian Cancer
        • 5.3.1.4. Lung Cancer
        • 5.3.1.5. Brain Tumor
      • 5.3.2. Global Antibody Drug Conjugate by: Conjugates (Volume)
        • 5.3.2.1. Small Molecules
        • 5.3.2.2. Protein Toxin
        • 5.3.2.3. Cytolytic Immunomodulatory Protein
        • 5.3.2.4. Biologically Active Peptide
        • 5.3.2.5. Enzymes
        • 5.3.2.6. Radionuclides
      • 5.3.3. Global Antibody Drug Conjugate by: Indications (Volume)
        • 5.3.3.1. Breast Cancer
        • 5.3.3.2. Lymphoma (Hl, Nhl, Alcl)
        • 5.3.3.3. Leukemia (Aml, All)
        • 5.3.3.4. Urothelial Cancer
        • 5.3.3.5. Lung Cancer (Nsclc, SCLC),
        • 5.3.3.6. Others
      • 5.3.4. Global Antibody Drug Conjugate by: Route Of Administration (Volume)
        • 5.3.4.1. Enteral Route
        • 5.3.4.2. Parenteral Route
      • 5.3.5. Global Antibody Drug Conjugate Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Antibody Drug Conjugate (Price)
  • 6. Antibody Drug Conjugate: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Progenics Pharmaceuticals(United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Genentech(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genmab (Denmark)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Amgen (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer HealthCare (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Celldex Therapeutics(United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Concortis Biotherapeutics(United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antibody Drug Conjugate Sale, by Application, Payloads , Conjugates, Linker, Indications, Route Of Administration and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Antibody Drug Conjugate (Value)
      • 7.2.1. Global Antibody Drug Conjugate by: Application (Value)
        • 7.2.1.1. Blood Cancer
        • 7.2.1.2. Breast Cancer
        • 7.2.1.3. Ovarian Cancer
        • 7.2.1.4. Lung Cancer
        • 7.2.1.5. Brain Tumor
      • 7.2.2. Global Antibody Drug Conjugate by: Conjugates (Value)
        • 7.2.2.1. Small Molecules
        • 7.2.2.2. Protein Toxin
        • 7.2.2.3. Cytolytic Immunomodulatory Protein
        • 7.2.2.4. Biologically Active Peptide
        • 7.2.2.5. Enzymes
        • 7.2.2.6. Radionuclides
      • 7.2.3. Global Antibody Drug Conjugate by: Indications (Value)
        • 7.2.3.1. Breast Cancer
        • 7.2.3.2. Lymphoma (Hl, Nhl, Alcl)
        • 7.2.3.3. Leukemia (Aml, All)
        • 7.2.3.4. Urothelial Cancer
        • 7.2.3.5. Lung Cancer (Nsclc, SCLC),
        • 7.2.3.6. Others
      • 7.2.4. Global Antibody Drug Conjugate by: Route Of Administration (Value)
        • 7.2.4.1. Enteral Route
        • 7.2.4.2. Parenteral Route
      • 7.2.5. Global Antibody Drug Conjugate Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Antibody Drug Conjugate (Volume)
      • 7.3.1. Global Antibody Drug Conjugate by: Application (Volume)
        • 7.3.1.1. Blood Cancer
        • 7.3.1.2. Breast Cancer
        • 7.3.1.3. Ovarian Cancer
        • 7.3.1.4. Lung Cancer
        • 7.3.1.5. Brain Tumor
      • 7.3.2. Global Antibody Drug Conjugate by: Conjugates (Volume)
        • 7.3.2.1. Small Molecules
        • 7.3.2.2. Protein Toxin
        • 7.3.2.3. Cytolytic Immunomodulatory Protein
        • 7.3.2.4. Biologically Active Peptide
        • 7.3.2.5. Enzymes
        • 7.3.2.6. Radionuclides
      • 7.3.3. Global Antibody Drug Conjugate by: Indications (Volume)
        • 7.3.3.1. Breast Cancer
        • 7.3.3.2. Lymphoma (Hl, Nhl, Alcl)
        • 7.3.3.3. Leukemia (Aml, All)
        • 7.3.3.4. Urothelial Cancer
        • 7.3.3.5. Lung Cancer (Nsclc, SCLC),
        • 7.3.3.6. Others
      • 7.3.4. Global Antibody Drug Conjugate by: Route Of Administration (Volume)
        • 7.3.4.1. Enteral Route
        • 7.3.4.2. Parenteral Route
      • 7.3.5. Global Antibody Drug Conjugate Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Antibody Drug Conjugate (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antibody Drug Conjugate: by Application(USD Million)
  • Table 2. Antibody Drug Conjugate Blood Cancer , by Region USD Million (2014-2019)
  • Table 3. Antibody Drug Conjugate Breast Cancer , by Region USD Million (2014-2019)
  • Table 4. Antibody Drug Conjugate Ovarian Cancer , by Region USD Million (2014-2019)
  • Table 5. Antibody Drug Conjugate Lung Cancer , by Region USD Million (2014-2019)
  • Table 6. Antibody Drug Conjugate Brain Tumor , by Region USD Million (2014-2019)
  • Table 7. Antibody Drug Conjugate: by Conjugates(USD Million)
  • Table 8. Antibody Drug Conjugate Small Molecules , by Region USD Million (2014-2019)
  • Table 9. Antibody Drug Conjugate Protein Toxin , by Region USD Million (2014-2019)
  • Table 10. Antibody Drug Conjugate Cytolytic Immunomodulatory Protein , by Region USD Million (2014-2019)
  • Table 11. Antibody Drug Conjugate Biologically Active Peptide , by Region USD Million (2014-2019)
  • Table 12. Antibody Drug Conjugate Enzymes , by Region USD Million (2014-2019)
  • Table 13. Antibody Drug Conjugate Radionuclides , by Region USD Million (2014-2019)
  • Table 14. Antibody Drug Conjugate: by Indications(USD Million)
  • Table 15. Antibody Drug Conjugate Breast Cancer , by Region USD Million (2014-2019)
  • Table 16. Antibody Drug Conjugate Lymphoma (Hl, Nhl, Alcl) , by Region USD Million (2014-2019)
  • Table 17. Antibody Drug Conjugate Leukemia (Aml, All) , by Region USD Million (2014-2019)
  • Table 18. Antibody Drug Conjugate Urothelial Cancer , by Region USD Million (2014-2019)
  • Table 19. Antibody Drug Conjugate Lung Cancer (Nsclc, SCLC), , by Region USD Million (2014-2019)
  • Table 20. Antibody Drug Conjugate Others , by Region USD Million (2014-2019)
  • Table 21. Antibody Drug Conjugate: by Route Of Administration(USD Million)
  • Table 22. Antibody Drug Conjugate Enteral Route , by Region USD Million (2014-2019)
  • Table 23. Antibody Drug Conjugate Parenteral Route , by Region USD Million (2014-2019)
  • Table 24. South America Antibody Drug Conjugate, by Country USD Million (2014-2019)
  • Table 25. South America Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 26. South America Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 27. South America Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 28. South America Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 29. South America Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 30. South America Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 31. Brazil Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 32. Brazil Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 33. Brazil Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 34. Brazil Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 35. Brazil Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 36. Brazil Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 37. Argentina Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 38. Argentina Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 39. Argentina Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 40. Argentina Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 41. Argentina Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 42. Argentina Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 43. Rest of South America Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 44. Rest of South America Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 45. Rest of South America Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 46. Rest of South America Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 47. Rest of South America Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 48. Rest of South America Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 49. Asia Pacific Antibody Drug Conjugate, by Country USD Million (2014-2019)
  • Table 50. Asia Pacific Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 51. Asia Pacific Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 52. Asia Pacific Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 53. Asia Pacific Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 54. Asia Pacific Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 55. Asia Pacific Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 56. China Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 57. China Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 58. China Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 59. China Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 60. China Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 61. China Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 62. Japan Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 63. Japan Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 64. Japan Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 65. Japan Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 66. Japan Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 67. Japan Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 68. India Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 69. India Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 70. India Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 71. India Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 72. India Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 73. India Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 74. South Korea Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 75. South Korea Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 76. South Korea Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 77. South Korea Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 78. South Korea Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 79. South Korea Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 80. Taiwan Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 81. Taiwan Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 82. Taiwan Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 83. Taiwan Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 84. Taiwan Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 85. Taiwan Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 86. Australia Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 87. Australia Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 88. Australia Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 89. Australia Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 90. Australia Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 91. Australia Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 92. Rest of Asia-Pacific Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 93. Rest of Asia-Pacific Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 94. Rest of Asia-Pacific Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 95. Rest of Asia-Pacific Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 96. Rest of Asia-Pacific Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 97. Rest of Asia-Pacific Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 98. Europe Antibody Drug Conjugate, by Country USD Million (2014-2019)
  • Table 99. Europe Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 100. Europe Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 101. Europe Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 102. Europe Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 103. Europe Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 104. Europe Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 105. Germany Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 106. Germany Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 107. Germany Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 108. Germany Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 109. Germany Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 110. Germany Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 111. France Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 112. France Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 113. France Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 114. France Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 115. France Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 116. France Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 117. Italy Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 118. Italy Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 119. Italy Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 120. Italy Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 121. Italy Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 122. Italy Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 123. United Kingdom Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 124. United Kingdom Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 125. United Kingdom Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 126. United Kingdom Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 127. United Kingdom Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 128. United Kingdom Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 129. Netherlands Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 130. Netherlands Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 131. Netherlands Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 132. Netherlands Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 133. Netherlands Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 134. Netherlands Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 135. Rest of Europe Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 136. Rest of Europe Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 137. Rest of Europe Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 138. Rest of Europe Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 139. Rest of Europe Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 140. Rest of Europe Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 141. MEA Antibody Drug Conjugate, by Country USD Million (2014-2019)
  • Table 142. MEA Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 143. MEA Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 144. MEA Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 145. MEA Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 146. MEA Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 147. MEA Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 148. Middle East Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 149. Middle East Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 150. Middle East Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 151. Middle East Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 152. Middle East Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 153. Middle East Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 154. Africa Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 155. Africa Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 156. Africa Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 157. Africa Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 158. Africa Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 159. Africa Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 160. North America Antibody Drug Conjugate, by Country USD Million (2014-2019)
  • Table 161. North America Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 162. North America Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 163. North America Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 164. North America Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 165. North America Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 166. North America Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 167. United States Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 168. United States Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 169. United States Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 170. United States Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 171. United States Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 172. United States Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 173. Canada Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 174. Canada Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 175. Canada Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 176. Canada Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 177. Canada Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 178. Canada Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 179. Mexico Antibody Drug Conjugate, by Application USD Million (2014-2019)
  • Table 180. Mexico Antibody Drug Conjugate, by Payloads USD Million (2014-2019)
  • Table 181. Mexico Antibody Drug Conjugate, by Conjugates USD Million (2014-2019)
  • Table 182. Mexico Antibody Drug Conjugate, by Linker USD Million (2014-2019)
  • Table 183. Mexico Antibody Drug Conjugate, by Indications USD Million (2014-2019)
  • Table 184. Mexico Antibody Drug Conjugate, by Route Of Administration USD Million (2014-2019)
  • Table 185. Antibody Drug Conjugate Sales: by Application(Tons)
  • Table 186. Antibody Drug Conjugate Sales Blood Cancer , by Region Tons (2014-2019)
  • Table 187. Antibody Drug Conjugate Sales Breast Cancer , by Region Tons (2014-2019)
  • Table 188. Antibody Drug Conjugate Sales Ovarian Cancer , by Region Tons (2014-2019)
  • Table 189. Antibody Drug Conjugate Sales Lung Cancer , by Region Tons (2014-2019)
  • Table 190. Antibody Drug Conjugate Sales Brain Tumor , by Region Tons (2014-2019)
  • Table 191. Antibody Drug Conjugate Sales: by Conjugates(Tons)
  • Table 192. Antibody Drug Conjugate Sales Small Molecules , by Region Tons (2014-2019)
  • Table 193. Antibody Drug Conjugate Sales Protein Toxin , by Region Tons (2014-2019)
  • Table 194. Antibody Drug Conjugate Sales Cytolytic Immunomodulatory Protein , by Region Tons (2014-2019)
  • Table 195. Antibody Drug Conjugate Sales Biologically Active Peptide , by Region Tons (2014-2019)
  • Table 196. Antibody Drug Conjugate Sales Enzymes , by Region Tons (2014-2019)
  • Table 197. Antibody Drug Conjugate Sales Radionuclides , by Region Tons (2014-2019)
  • Table 198. Antibody Drug Conjugate Sales: by Indications(Tons)
  • Table 199. Antibody Drug Conjugate Sales Breast Cancer , by Region Tons (2014-2019)
  • Table 200. Antibody Drug Conjugate Sales Lymphoma (Hl, Nhl, Alcl) , by Region Tons (2014-2019)
  • Table 201. Antibody Drug Conjugate Sales Leukemia (Aml, All) , by Region Tons (2014-2019)
  • Table 202. Antibody Drug Conjugate Sales Urothelial Cancer , by Region Tons (2014-2019)
  • Table 203. Antibody Drug Conjugate Sales Lung Cancer (Nsclc, SCLC), , by Region Tons (2014-2019)
  • Table 204. Antibody Drug Conjugate Sales Others , by Region Tons (2014-2019)
  • Table 205. Antibody Drug Conjugate Sales: by Route Of Administration(Tons)
  • Table 206. Antibody Drug Conjugate Sales Enteral Route , by Region Tons (2014-2019)
  • Table 207. Antibody Drug Conjugate Sales Parenteral Route , by Region Tons (2014-2019)
  • Table 208. South America Antibody Drug Conjugate Sales, by Country Tons (2014-2019)
  • Table 209. South America Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 210. South America Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 211. South America Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 212. South America Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 213. South America Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 214. South America Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 215. Brazil Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 216. Brazil Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 217. Brazil Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 218. Brazil Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 219. Brazil Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 220. Brazil Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 221. Argentina Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 222. Argentina Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 223. Argentina Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 224. Argentina Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 225. Argentina Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 226. Argentina Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 227. Rest of South America Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 228. Rest of South America Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 229. Rest of South America Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 230. Rest of South America Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 231. Rest of South America Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 232. Rest of South America Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 233. Asia Pacific Antibody Drug Conjugate Sales, by Country Tons (2014-2019)
  • Table 234. Asia Pacific Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 235. Asia Pacific Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 236. Asia Pacific Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 237. Asia Pacific Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 238. Asia Pacific Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 239. Asia Pacific Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 240. China Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 241. China Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 242. China Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 243. China Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 244. China Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 245. China Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 246. Japan Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 247. Japan Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 248. Japan Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 249. Japan Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 250. Japan Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 251. Japan Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 252. India Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 253. India Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 254. India Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 255. India Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 256. India Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 257. India Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 258. South Korea Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 259. South Korea Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 260. South Korea Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 261. South Korea Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 262. South Korea Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 263. South Korea Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 264. Taiwan Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 265. Taiwan Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 266. Taiwan Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 267. Taiwan Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 268. Taiwan Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 269. Taiwan Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 270. Australia Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 271. Australia Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 272. Australia Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 273. Australia Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 274. Australia Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 275. Australia Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 276. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 277. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 278. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 279. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 280. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 281. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 282. Europe Antibody Drug Conjugate Sales, by Country Tons (2014-2019)
  • Table 283. Europe Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 284. Europe Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 285. Europe Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 286. Europe Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 287. Europe Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 288. Europe Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 289. Germany Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 290. Germany Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 291. Germany Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 292. Germany Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 293. Germany Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 294. Germany Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 295. France Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 296. France Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 297. France Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 298. France Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 299. France Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 300. France Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 301. Italy Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 302. Italy Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 303. Italy Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 304. Italy Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 305. Italy Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 306. Italy Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 307. United Kingdom Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 308. United Kingdom Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 309. United Kingdom Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 310. United Kingdom Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 311. United Kingdom Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 312. United Kingdom Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 313. Netherlands Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 314. Netherlands Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 315. Netherlands Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 316. Netherlands Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 317. Netherlands Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 318. Netherlands Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 319. Rest of Europe Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 320. Rest of Europe Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 321. Rest of Europe Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 322. Rest of Europe Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 323. Rest of Europe Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 324. Rest of Europe Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 325. MEA Antibody Drug Conjugate Sales, by Country Tons (2014-2019)
  • Table 326. MEA Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 327. MEA Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 328. MEA Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 329. MEA Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 330. MEA Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 331. MEA Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 332. Middle East Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 333. Middle East Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 334. Middle East Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 335. Middle East Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 336. Middle East Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 337. Middle East Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 338. Africa Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 339. Africa Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 340. Africa Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 341. Africa Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 342. Africa Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 343. Africa Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 344. North America Antibody Drug Conjugate Sales, by Country Tons (2014-2019)
  • Table 345. North America Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 346. North America Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 347. North America Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 348. North America Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 349. North America Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 350. North America Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 351. United States Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 352. United States Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 353. United States Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 354. United States Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 355. United States Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 356. United States Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 357. Canada Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 358. Canada Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 359. Canada Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 360. Canada Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 361. Canada Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 362. Canada Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 363. Mexico Antibody Drug Conjugate Sales, by Application Tons (2014-2019)
  • Table 364. Mexico Antibody Drug Conjugate Sales, by Payloads Tons (2014-2019)
  • Table 365. Mexico Antibody Drug Conjugate Sales, by Conjugates Tons (2014-2019)
  • Table 366. Mexico Antibody Drug Conjugate Sales, by Linker Tons (2014-2019)
  • Table 367. Mexico Antibody Drug Conjugate Sales, by Indications Tons (2014-2019)
  • Table 368. Mexico Antibody Drug Conjugate Sales, by Route Of Administration Tons (2014-2019)
  • Table 369. Company Basic Information, Sales Area and Its Competitors
  • Table 370. Company Basic Information, Sales Area and Its Competitors
  • Table 371. Company Basic Information, Sales Area and Its Competitors
  • Table 372. Company Basic Information, Sales Area and Its Competitors
  • Table 373. Company Basic Information, Sales Area and Its Competitors
  • Table 374. Company Basic Information, Sales Area and Its Competitors
  • Table 375. Company Basic Information, Sales Area and Its Competitors
  • Table 376. Company Basic Information, Sales Area and Its Competitors
  • Table 377. Company Basic Information, Sales Area and Its Competitors
  • Table 378. Company Basic Information, Sales Area and Its Competitors
  • Table 379. Antibody Drug Conjugate: by Application(USD Million)
  • Table 380. Antibody Drug Conjugate Blood Cancer , by Region USD Million (2020-2025)
  • Table 381. Antibody Drug Conjugate Breast Cancer , by Region USD Million (2020-2025)
  • Table 382. Antibody Drug Conjugate Ovarian Cancer , by Region USD Million (2020-2025)
  • Table 383. Antibody Drug Conjugate Lung Cancer , by Region USD Million (2020-2025)
  • Table 384. Antibody Drug Conjugate Brain Tumor , by Region USD Million (2020-2025)
  • Table 385. Antibody Drug Conjugate: by Conjugates(USD Million)
  • Table 386. Antibody Drug Conjugate Small Molecules , by Region USD Million (2020-2025)
  • Table 387. Antibody Drug Conjugate Protein Toxin , by Region USD Million (2020-2025)
  • Table 388. Antibody Drug Conjugate Cytolytic Immunomodulatory Protein , by Region USD Million (2020-2025)
  • Table 389. Antibody Drug Conjugate Biologically Active Peptide , by Region USD Million (2020-2025)
  • Table 390. Antibody Drug Conjugate Enzymes , by Region USD Million (2020-2025)
  • Table 391. Antibody Drug Conjugate Radionuclides , by Region USD Million (2020-2025)
  • Table 392. Antibody Drug Conjugate: by Indications(USD Million)
  • Table 393. Antibody Drug Conjugate Breast Cancer , by Region USD Million (2020-2025)
  • Table 394. Antibody Drug Conjugate Lymphoma (Hl, Nhl, Alcl) , by Region USD Million (2020-2025)
  • Table 395. Antibody Drug Conjugate Leukemia (Aml, All) , by Region USD Million (2020-2025)
  • Table 396. Antibody Drug Conjugate Urothelial Cancer , by Region USD Million (2020-2025)
  • Table 397. Antibody Drug Conjugate Lung Cancer (Nsclc, SCLC), , by Region USD Million (2020-2025)
  • Table 398. Antibody Drug Conjugate Others , by Region USD Million (2020-2025)
  • Table 399. Antibody Drug Conjugate: by Route Of Administration(USD Million)
  • Table 400. Antibody Drug Conjugate Enteral Route , by Region USD Million (2020-2025)
  • Table 401. Antibody Drug Conjugate Parenteral Route , by Region USD Million (2020-2025)
  • Table 402. South America Antibody Drug Conjugate, by Country USD Million (2020-2025)
  • Table 403. South America Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 404. South America Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 405. South America Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 406. South America Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 407. South America Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 408. South America Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 409. Brazil Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 410. Brazil Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 411. Brazil Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 412. Brazil Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 413. Brazil Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 414. Brazil Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 415. Argentina Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 416. Argentina Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 417. Argentina Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 418. Argentina Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 419. Argentina Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 420. Argentina Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 421. Rest of South America Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 422. Rest of South America Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 423. Rest of South America Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 424. Rest of South America Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 425. Rest of South America Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 426. Rest of South America Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 427. Asia Pacific Antibody Drug Conjugate, by Country USD Million (2020-2025)
  • Table 428. Asia Pacific Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 429. Asia Pacific Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 430. Asia Pacific Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 431. Asia Pacific Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 432. Asia Pacific Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 433. Asia Pacific Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 434. China Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 435. China Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 436. China Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 437. China Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 438. China Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 439. China Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 440. Japan Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 441. Japan Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 442. Japan Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 443. Japan Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 444. Japan Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 445. Japan Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 446. India Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 447. India Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 448. India Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 449. India Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 450. India Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 451. India Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 452. South Korea Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 453. South Korea Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 454. South Korea Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 455. South Korea Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 456. South Korea Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 457. South Korea Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 458. Taiwan Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 459. Taiwan Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 460. Taiwan Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 461. Taiwan Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 462. Taiwan Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 463. Taiwan Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 464. Australia Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 465. Australia Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 466. Australia Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 467. Australia Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 468. Australia Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 469. Australia Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 470. Rest of Asia-Pacific Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 471. Rest of Asia-Pacific Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 472. Rest of Asia-Pacific Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 473. Rest of Asia-Pacific Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 474. Rest of Asia-Pacific Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 475. Rest of Asia-Pacific Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 476. Europe Antibody Drug Conjugate, by Country USD Million (2020-2025)
  • Table 477. Europe Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 478. Europe Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 479. Europe Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 480. Europe Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 481. Europe Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 482. Europe Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 483. Germany Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 484. Germany Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 485. Germany Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 486. Germany Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 487. Germany Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 488. Germany Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 489. France Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 490. France Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 491. France Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 492. France Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 493. France Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 494. France Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 495. Italy Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 496. Italy Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 497. Italy Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 498. Italy Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 499. Italy Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 500. Italy Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 501. United Kingdom Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 502. United Kingdom Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 503. United Kingdom Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 504. United Kingdom Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 505. United Kingdom Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 506. United Kingdom Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 507. Netherlands Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 508. Netherlands Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 509. Netherlands Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 510. Netherlands Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 511. Netherlands Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 512. Netherlands Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 513. Rest of Europe Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 514. Rest of Europe Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 515. Rest of Europe Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 516. Rest of Europe Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 517. Rest of Europe Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 518. Rest of Europe Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 519. MEA Antibody Drug Conjugate, by Country USD Million (2020-2025)
  • Table 520. MEA Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 521. MEA Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 522. MEA Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 523. MEA Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 524. MEA Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 525. MEA Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 526. Middle East Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 527. Middle East Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 528. Middle East Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 529. Middle East Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 530. Middle East Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 531. Middle East Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 532. Africa Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 533. Africa Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 534. Africa Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 535. Africa Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 536. Africa Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 537. Africa Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 538. North America Antibody Drug Conjugate, by Country USD Million (2020-2025)
  • Table 539. North America Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 540. North America Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 541. North America Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 542. North America Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 543. North America Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 544. North America Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 545. United States Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 546. United States Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 547. United States Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 548. United States Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 549. United States Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 550. United States Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 551. Canada Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 552. Canada Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 553. Canada Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 554. Canada Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 555. Canada Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 556. Canada Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 557. Mexico Antibody Drug Conjugate, by Application USD Million (2020-2025)
  • Table 558. Mexico Antibody Drug Conjugate, by Payloads USD Million (2020-2025)
  • Table 559. Mexico Antibody Drug Conjugate, by Conjugates USD Million (2020-2025)
  • Table 560. Mexico Antibody Drug Conjugate, by Linker USD Million (2020-2025)
  • Table 561. Mexico Antibody Drug Conjugate, by Indications USD Million (2020-2025)
  • Table 562. Mexico Antibody Drug Conjugate, by Route Of Administration USD Million (2020-2025)
  • Table 563. Antibody Drug Conjugate Sales: by Application(Tons)
  • Table 564. Antibody Drug Conjugate Sales Blood Cancer , by Region Tons (2020-2025)
  • Table 565. Antibody Drug Conjugate Sales Breast Cancer , by Region Tons (2020-2025)
  • Table 566. Antibody Drug Conjugate Sales Ovarian Cancer , by Region Tons (2020-2025)
  • Table 567. Antibody Drug Conjugate Sales Lung Cancer , by Region Tons (2020-2025)
  • Table 568. Antibody Drug Conjugate Sales Brain Tumor , by Region Tons (2020-2025)
  • Table 569. Antibody Drug Conjugate Sales: by Conjugates(Tons)
  • Table 570. Antibody Drug Conjugate Sales Small Molecules , by Region Tons (2020-2025)
  • Table 571. Antibody Drug Conjugate Sales Protein Toxin , by Region Tons (2020-2025)
  • Table 572. Antibody Drug Conjugate Sales Cytolytic Immunomodulatory Protein , by Region Tons (2020-2025)
  • Table 573. Antibody Drug Conjugate Sales Biologically Active Peptide , by Region Tons (2020-2025)
  • Table 574. Antibody Drug Conjugate Sales Enzymes , by Region Tons (2020-2025)
  • Table 575. Antibody Drug Conjugate Sales Radionuclides , by Region Tons (2020-2025)
  • Table 576. Antibody Drug Conjugate Sales: by Indications(Tons)
  • Table 577. Antibody Drug Conjugate Sales Breast Cancer , by Region Tons (2020-2025)
  • Table 578. Antibody Drug Conjugate Sales Lymphoma (Hl, Nhl, Alcl) , by Region Tons (2020-2025)
  • Table 579. Antibody Drug Conjugate Sales Leukemia (Aml, All) , by Region Tons (2020-2025)
  • Table 580. Antibody Drug Conjugate Sales Urothelial Cancer , by Region Tons (2020-2025)
  • Table 581. Antibody Drug Conjugate Sales Lung Cancer (Nsclc, SCLC), , by Region Tons (2020-2025)
  • Table 582. Antibody Drug Conjugate Sales Others , by Region Tons (2020-2025)
  • Table 583. Antibody Drug Conjugate Sales: by Route Of Administration(Tons)
  • Table 584. Antibody Drug Conjugate Sales Enteral Route , by Region Tons (2020-2025)
  • Table 585. Antibody Drug Conjugate Sales Parenteral Route , by Region Tons (2020-2025)
  • Table 586. South America Antibody Drug Conjugate Sales, by Country Tons (2020-2025)
  • Table 587. South America Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 588. South America Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 589. South America Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 590. South America Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 591. South America Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 592. South America Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 593. Brazil Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 594. Brazil Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 595. Brazil Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 596. Brazil Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 597. Brazil Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 598. Brazil Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 599. Argentina Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 600. Argentina Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 601. Argentina Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 602. Argentina Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 603. Argentina Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 604. Argentina Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 605. Rest of South America Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 606. Rest of South America Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 607. Rest of South America Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 608. Rest of South America Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 609. Rest of South America Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 610. Rest of South America Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 611. Asia Pacific Antibody Drug Conjugate Sales, by Country Tons (2020-2025)
  • Table 612. Asia Pacific Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 613. Asia Pacific Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 614. Asia Pacific Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 615. Asia Pacific Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 616. Asia Pacific Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 617. Asia Pacific Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 618. China Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 619. China Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 620. China Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 621. China Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 622. China Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 623. China Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 624. Japan Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 625. Japan Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 626. Japan Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 627. Japan Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 628. Japan Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 629. Japan Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 630. India Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 631. India Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 632. India Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 633. India Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 634. India Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 635. India Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 636. South Korea Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 637. South Korea Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 638. South Korea Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 639. South Korea Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 640. South Korea Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 641. South Korea Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 642. Taiwan Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 643. Taiwan Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 644. Taiwan Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 645. Taiwan Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 646. Taiwan Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 647. Taiwan Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 648. Australia Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 649. Australia Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 650. Australia Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 651. Australia Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 652. Australia Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 653. Australia Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 654. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 655. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 656. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 657. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 658. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 659. Rest of Asia-Pacific Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 660. Europe Antibody Drug Conjugate Sales, by Country Tons (2020-2025)
  • Table 661. Europe Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 662. Europe Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 663. Europe Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 664. Europe Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 665. Europe Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 666. Europe Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 667. Germany Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 668. Germany Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 669. Germany Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 670. Germany Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 671. Germany Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 672. Germany Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 673. France Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 674. France Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 675. France Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 676. France Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 677. France Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 678. France Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 679. Italy Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 680. Italy Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 681. Italy Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 682. Italy Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 683. Italy Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 684. Italy Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 685. United Kingdom Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 686. United Kingdom Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 687. United Kingdom Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 688. United Kingdom Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 689. United Kingdom Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 690. United Kingdom Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 691. Netherlands Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 692. Netherlands Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 693. Netherlands Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 694. Netherlands Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 695. Netherlands Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 696. Netherlands Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 697. Rest of Europe Antibody Drug Conjugate Sales, by Application Tons (2020-2025)
  • Table 698. Rest of Europe Antibody Drug Conjugate Sales, by Payloads Tons (2020-2025)
  • Table 699. Rest of Europe Antibody Drug Conjugate Sales, by Conjugates Tons (2020-2025)
  • Table 700. Rest of Europe Antibody Drug Conjugate Sales, by Linker Tons (2020-2025)
  • Table 701. Rest of Europe Antibody Drug Conjugate Sales, by Indications Tons (2020-2025)
  • Table 702. Rest of Europe Antibody Drug Conjugate Sales, by Route Of Administration Tons (2020-2025)
  • Table 703. MEA Antibody Drug Conjugate Sales, by Country Tons (2020-2025)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antibody Drug Conjugate: by Application USD Million (2014-2019)
  • Figure 5. Global Antibody Drug Conjugate: by Conjugates USD Million (2014-2019)
  • Figure 6. Global Antibody Drug Conjugate: by Indications USD Million (2014-2019)
  • Figure 7. Global Antibody Drug Conjugate: by Route Of Administration USD Million (2014-2019)
  • Figure 8. South America Antibody Drug Conjugate Share (%), by Country
  • Figure 9. Asia Pacific Antibody Drug Conjugate Share (%), by Country
  • Figure 10. Europe Antibody Drug Conjugate Share (%), by Country
  • Figure 11. MEA Antibody Drug Conjugate Share (%), by Country
  • Figure 12. North America Antibody Drug Conjugate Share (%), by Country
  • Figure 13. Global Antibody Drug Conjugate: by Application Tons (2014-2019)
  • Figure 14. Global Antibody Drug Conjugate: by Conjugates Tons (2014-2019)
  • Figure 15. Global Antibody Drug Conjugate: by Indications Tons (2014-2019)
  • Figure 16. Global Antibody Drug Conjugate: by Route Of Administration Tons (2014-2019)
  • Figure 17. South America Antibody Drug Conjugate Share (%), by Country
  • Figure 18. Asia Pacific Antibody Drug Conjugate Share (%), by Country
  • Figure 19. Europe Antibody Drug Conjugate Share (%), by Country
  • Figure 20. MEA Antibody Drug Conjugate Share (%), by Country
  • Figure 21. North America Antibody Drug Conjugate Share (%), by Country
  • Figure 22. Global Antibody Drug Conjugate share by Players 2019 (%)
  • Figure 23. Global Antibody Drug Conjugate share by Players (Top 3) 2019(%)
  • Figure 24. Global Antibody Drug Conjugate share by Players (Top 5) 2019(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer (United States) Revenue: by Geography 2019
  • Figure 28. Progenics Pharmaceuticals(United States) Revenue, Net Income and Gross profit
  • Figure 29. Progenics Pharmaceuticals(United States) Revenue: by Geography 2019
  • Figure 30. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Novartis (Switzerland) Revenue: by Geography 2019
  • Figure 32. Eli Lilly(United States) Revenue, Net Income and Gross profit
  • Figure 33. Eli Lilly(United States) Revenue: by Geography 2019
  • Figure 34. Genentech(United States) Revenue, Net Income and Gross profit
  • Figure 35. Genentech(United States) Revenue: by Geography 2019
  • Figure 36. Genmab (Denmark) Revenue, Net Income and Gross profit
  • Figure 37. Genmab (Denmark) Revenue: by Geography 2019
  • Figure 38. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 39. Amgen (United States) Revenue: by Geography 2019
  • Figure 40. Bayer HealthCare (Germany) Revenue, Net Income and Gross profit
  • Figure 41. Bayer HealthCare (Germany) Revenue: by Geography 2019
  • Figure 42. Celldex Therapeutics(United States) Revenue, Net Income and Gross profit
  • Figure 43. Celldex Therapeutics(United States) Revenue: by Geography 2019
  • Figure 44. Concortis Biotherapeutics(United States) Revenue, Net Income and Gross profit
  • Figure 45. Concortis Biotherapeutics(United States) Revenue: by Geography 2019
  • Figure 46. Global Antibody Drug Conjugate: by Application USD Million (2020-2025)
  • Figure 47. Global Antibody Drug Conjugate: by Conjugates USD Million (2020-2025)
  • Figure 48. Global Antibody Drug Conjugate: by Indications USD Million (2020-2025)
  • Figure 49. Global Antibody Drug Conjugate: by Route Of Administration USD Million (2020-2025)
  • Figure 50. South America Antibody Drug Conjugate Share (%), by Country
  • Figure 51. Asia Pacific Antibody Drug Conjugate Share (%), by Country
  • Figure 52. Europe Antibody Drug Conjugate Share (%), by Country
  • Figure 53. MEA Antibody Drug Conjugate Share (%), by Country
  • Figure 54. North America Antibody Drug Conjugate Share (%), by Country
  • Figure 55. Global Antibody Drug Conjugate: by Application Tons (2020-2025)
  • Figure 56. Global Antibody Drug Conjugate: by Conjugates Tons (2020-2025)
  • Figure 57. Global Antibody Drug Conjugate: by Indications Tons (2020-2025)
  • Figure 58. Global Antibody Drug Conjugate: by Route Of Administration Tons (2020-2025)
  • Figure 59. South America Antibody Drug Conjugate Share (%), by Country
  • Figure 60. Asia Pacific Antibody Drug Conjugate Share (%), by Country
  • Figure 61. Europe Antibody Drug Conjugate Share (%), by Country
  • Figure 62. MEA Antibody Drug Conjugate Share (%), by Country
  • Figure 63. North America Antibody Drug Conjugate Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer (United States)
  • Progenics Pharmaceuticals(United States)
  • Novartis (Switzerland)
  • Eli Lilly(United States)
  • Genentech(United States)
  • Genmab (Denmark)
  • Amgen (United States)
  • Bayer HealthCare (Germany)
  • Celldex Therapeutics(United States)
  • Concortis Biotherapeutics(United States)
Additional players considered in the study are as follows:
Mersana Therapeutics(United States) , Millennium Pharmaceuticals(United States) , AbbVie (United States) , Agensys(United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation